N. Rao

发表

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.

S. Akinaga, Y. Shiotsu, J. Cortes, 2009, Blood.

ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models

N. Damle, H. Usansky, Sanjeeva P. Reddy, 2021, Molecular Cancer Therapeutics.

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study†

L. Denis, S. Forman, J. Fowler, 2019, The British journal of dermatology.

Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis.

L. Denis, Ning Zhang, R. Bissonnette, 2019, The Journal of allergy and clinical immunology.

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

W. Blackwelder, K. Ella, S. Panda, 2021, The Lancet.

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

S. Akinaga, H. Kantarjian, J. Cortes, 2008 .

Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition

S. Akinaga, Y. Shiotsu, J. Karp, 2008 .

ASN001, a novel CYP17 lyase inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Safety/tolerability and early activity in a multicenter phase 1/2 trial.

A. Tolcher, A. Pantuck, L. Denis, 2016 .

Oral SYK/JAK Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study.

Yusong Chen, J. Fowler, R. Bissonnette, 2023, Journal of the American Academy of Dermatology.

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

S. Akinaga, H. Kantarjian, J. Cortes, 2007 .